<SEC-DOCUMENT>0001041885-11-000063.txt : 20110607
<SEC-HEADER>0001041885-11-000063.hdr.sgml : 20110607
<ACCEPTANCE-DATETIME>20110607163129
ACCESSION NUMBER:		0001041885-11-000063
CONFORMED SUBMISSION TYPE:	SC 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20110607
DATE AS OF CHANGE:		20110607

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALSERES PHARMACEUTICALS INC /DE
		CENTRAL INDEX KEY:			0000094784
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870277826
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-07548
		FILM NUMBER:		11898879

	BUSINESS ADDRESS:	
		STREET 1:		239 SOUTH STREET
		CITY:			HOPKINTON
		STATE:			MA
		ZIP:			01748
		BUSINESS PHONE:		508-497-2360

	MAIL ADDRESS:	
		STREET 1:		239 SOUTH STREET
		CITY:			HOPKINTON
		STATE:			MA
		ZIP:			01748

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOSTON LIFE SCIENCES INC /DE
		DATE OF NAME CHANGE:	19950706

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GREENWICH PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STRATEGIC MEDICAL RESEARCH CORP /DE
		DATE OF NAME CHANGE:	19790521

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INGALLS & SNYDER VALUE PARTNERS L P
		CENTRAL INDEX KEY:			0000895302
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		SC 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		61 BROADWAY
		STREET 2:		C/O INGALLS & SNYDER
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10006
		BUSINESS PHONE:		2122697897

	MAIL ADDRESS:	
		STREET 1:		C/O INGALLS & SNYDER
		STREET 2:		61 BROADWAY
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10006
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13G/A
<SEQUENCE>1
<FILENAME>alspha13gaisvpjune11.txt
<TEXT>


                      UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C.  20549


_____________________________
OMB APPROVAL
OMB NUMBER: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response....11
_____________________________


                                 SCHEDULE 13G/A


                   Under the Securities Exchange Act of 1934
                         (Amendment No._4___ )*


                    	ALSERES PHARMACEUTICALS, INC
             -----------------------------------------------------
                                (Name of Issuer)

                 		COMMON STOCK
             -----------------------------------------------------
                         (Title of Class of Securities)

                   		   021152103
             -----------------------------------------------------
                                 (CUSIP Number)

				   06/01/11
             -----------------------------------------------------
            (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

[] Rule 13d-1(b)
[X] Rule 13d-1(c)
[] Rule 13d-1(d)


----------
*The  remainder of this cover page shall be filled out for a reporting  person's
initial filing on this form with respect to the subject class of securities, and
for any  subsequent  amendment  containing  information  which  would  alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of
1934 ("Act") or otherwise  subject to the liabilities of that section of the Act
but  shall be  subject  to all other  provisions  of the Act  (however,  see the
Notes).


<PAGE>

CUSIP No.  021152103


--------------------------------------------------------------------------------
   1.  NAME OF REPORTING PERSON(S)
       S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON(S)

	INGALLS & SNYDER VALUE PARTNERS, LP
	13-3694561


--------------------------------------------------------------------------------
   2.  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

         (a)  [  ]
         (b)  [  ]


--------------------------------------------------------------------------------
   3.  SEC USE ONLY


--------------------------------------------------------------------------------
   4.  CITIZENSHIP OR PLACE OF ORGANIZATION


     NEW YORK STATE

--------------------------------------------------------------------------------
   NUMBER OF      5.   SOLE VOTING POWER
     SHARES             3,476,174
BENEFICIALLY    --------------------------------------------------------------
    OWNED BY      6.   SHARED VOTING POWER
      EACH              0
   REPORTING      --------------------------------------------------------------
     PERSON       7.   SOLE DISPOSITIVE POWER
      WITH              0
--------------------------------------------------------------
                  8.   SHARED DISPOSITIVE POWER

                    3,476,174
--------------------------------------------------------------------------------
   9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                    3,476,174
--------------------------------------------------------------------------------
  10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*


--------------------------------------------------------------------------------
  11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

             9.99%
--------------------------------------------------------------------------------
  12.  TYPE OF REPORTING PERSON*

                  PN
--------------------------------------------------------------------------------


Item 1.     (a)   Name of Issuer:

                 	ALSERES PHARMACEUTICALS, INC.
                  --------------------------------------------------------------
            (b)   Address of Issuer's Principal Executive Offices:

                	239 SOUTH STREET
			HOPKINTON, MA 01748
                  --------------------------------------------------------------
Item 2.     (a)   Name of Person Filing:


	           INGALLS & SNYDER VALUE PARTNERS, LP
                  --------------------------------------------------------------
            (b)   Address of Principal Business Office, or if None, Residence:


	          61 BROADWAY, NEW YORK, NY 10006


                  --------------------------------------------------------------
            (c)   Citizenship:
                             NEW YORK STATE
                  --------------------------------------------------------------
            (d)   Title of Class of Securities:
                  		COMMON STOCK
                  --------------------------------------------------------------
            (e)   CUSIP Number:
                                021152103
                  --------------------------------------------------------------


Item 3.     If this statement  is filed  pursuant to Rules 240.13d-(1), or
            13d-2(b) or (c), check whether the person filing is a:

            (a)   [ ]   Broker or Dealer  registered under Section  15 of  the
                        Act, (15 U.S.C 78o)

            (b)   [ ]   Bank as defined in Section 3(a)(6) of the
			Act, (15 U.S.C 78c)

            (c)   [ ]   Insurance Company  as defined  in Section  3(a)(19) of
                        the Act, (15 U.S.C 78c)

            (d)   [ ]   Investment Company registered under  Section 8 of  the
                        Investment Company Act of 1940 (15 U.S.C 80a-8)

            (e)   [ ]   Investment Adviser in accordance with Section
			240.13d-1(b)(1)(ii)(E)

            (f)   [ ]   Employee Benefit Plan or endowment fund in accordance
			to Section 240.13d-1(b)(ii)(F)

            (g)   [ ]   A parent holding company or control person in
			accordance with Section 240.13d-1(b)(1)(ii)(G)


	    (h)   [ ]   A savings associations as defined in Section 3(b) of the
			Federal Deposit Insurance Act (12 U.S.C 1813)

	    (i)	  [ ]	A church plan that is excluded from the definition of an
			investment company under section 3(c)(14) of
			the Investment Company Act of 1940 (15 U.S.C 80a-3)

	    (j)   [ ] 	Group, in accordance with Section 240.13d-1(b)(1)(ii)(J)


Item 4.     Ownership.

            (a) Amount beneficially owned:  3,476,174----------,

            (b) Percent of class: 9.99%----------------------,

            (c) Number of shares as to which such person has:

                  (i) Sole power to vote or to direct the vote
			 3,476,174--,

                  (ii) Shared power to vote or to direct the vote
			0------,

                  (iii) Sole power to dispose or to direct the disposition of
			0-----,


                  (iv) Shared power to dispose or to direct the disposition of
			 3,476,174------


Item 5.     Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof
the reporting person has ceased to be the beneficial owner of more than five
percent of the class of securities, check the following [ ].
		INAPPLICABLE

Item 6.     Ownership of More Than Five Percent on Behalf of Another Person.

		INAPPLICABLE

Item 7.     Identification and Classification of the Subsidiary which Acquired
            the Security Being Reported on By the Parent Holding Company.

		INAPPLICABLE

Item 8.     Identification and Classification of Members of the Group.

		INAPPLICABLE

Item 9.     Notice of Dissolution of Group.

		INAPPLICABLE


Item 10.    Certification.


            By  signing  below I certify  that,  to the  best  of  my knowledge
and belief, the securities referred to above were acquired and are held in the
ordinary  course of business  and were not  acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities  and were not acquired and are not held in connection
with or as a participant in any  transaction  having that purpose or effect.

                                  Signature.


            After reasonable inquiry and to the best of my knowledge and
            belief, I certify  that the  information  set  forth in this
            statement is true, complete and correct.

Date: 06/07/11

BY:INGALLS & SNYDER VALUE PARTNERS, LP

/s/ THOMAS O. BOUCHER, JR
----------------------------------
                      (Signature)*

THOMAS O. BOUCHER, JR
----------------------------------
GENERAL PARTNER
                      (Name/Title)

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>